Cymabay Therapeutics (CBAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2013 | 12-2012 | 12-2006 | |
| Assets | |||
| Current Assets | |||
| Cash & Cash Equivalents | 24,401 | 7,726 | N/A |
| Marketable Securities | 6,843 | N/A | N/A |
| Receivables | 178 | 117 | N/A |
| Other current assets | 453 | 0 | 0 |
| TOTAL | $32,239 | $7,990 | $N/A |
| Non-Current Assets | |||
| PPE Net | 3 | 84 | N/A |
| Other Non-Current Assets | 258 | 42 | 0 |
| TOTAL | $261 | $126 | $N/A |
| Total Assets | $32,500 | $8,116 | $N/A |
| Liabilities | |||
| Current Liabilities | |||
| Short Term Debt | 38 | N/A | N/A |
| Accounts payable and accrued liabilities | 733 | 3,223 | 0 |
| Accrued Expenses | 2,251 | 990 | N/A |
| Other current liabilities | 6,466 | N/A | N/A |
| TOTAL | $9,488 | $17,950 | $N/A |
| Non-Current Liabilities | |||
| Long Term Debt | 4,407 | N/A | N/A |
| Other Non-Current Liabilities | 9 | 36 | 0 |
| TOTAL | $4,416 | $36 | $N/A |
| Total Liabilities | $13,904 | $17,986 | $N/A |
| Shareholders' Equity | |||
| Shares Outstanding, K | 10,065 | N/A | N/A |
| Common Shares | 1 | N/A | N/A |
| Retained earnings | -348,842 | -329,480 | N/A |
| Other shareholders' equity | 2 | 318,697 | 0 |
| TOTAL | $18,596 | $-9,870 | $N/A |
| Total Liabilities And Equity | $32,500 | $8,116 | $0 |